Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Hillsdale Investment Management Inc.

Posted by Brian Himes on Jul 14th, 2026

Hillsdale Investment Management Inc. boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 4.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 743,679 shares of the company’s stock after purchasing an additional 29,150 shares during the period. Hillsdale Investment Management Inc.’s holdings in Amneal Pharmaceuticals were worth $9,244,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Amneal Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock valued at $793,000 after purchasing an additional 4,178 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 32.6% during the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after buying an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Amneal Pharmaceuticals by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock worth $2,807,000 after buying an additional 16,536 shares during the period. Finally, Creative Planning boosted its holdings in Amneal Pharmaceuticals by 61.9% in the second quarter. Creative Planning now owns 23,896 shares of the company’s stock valued at $193,000 after acquiring an additional 9,136 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of research reports. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. UBS Group initiated coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective on the stock. Barclays lifted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday. Finally, Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $15.80.

View Our Latest Report on AMRX

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $17.18 on Tuesday. Amneal Pharmaceuticals, Inc. has a 1-year low of $7.66 and a 1-year high of $17.86. The business has a 50-day moving average of $14.73 and a 200-day moving average of $13.77. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of 45.21 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Profile

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.